Skip to main content
Premium Trial:

Request an Annual Quote

Sirnaomics Partners with Chinese Pharma on Wound-Healing Drug

Premium

Sirnaomics said this week that it has signed a deal with an undisclosed Chinese pharmaceutical company to co-develop an siRNA-based drug for scarless wound healing.

The drug, STP705, uses a polymeric nanoparticle to enhance topical delivery of siRNAs targeting the TGF-beta 1 and Cox-2 genes to open wounds, Sirnaomics said.

The new alliance "provides financial resources and local capabilities allowing acceleration through the clinical study and regulatory process in China," the company added.

The arrangement, which includes "licensing, funding, and market-sharing structures," is limited to the greater China area, including Hong Kong, Macau, and Taiwan. Additional terms were not disclosed.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.